Evaluation of treatment benefits: clinical endpoints relevant to patients.
(1) Evaluation of treatment benefits needs to focus on the health outcomes of greatest importance to patients. Endpoints for evaluating treatment efficacy should be based on clinical outcomes; (2) "Surrogate" endpoints do not directly affect patients' health but can be useful in some clinical situations. The adverse effects of treatment must also be assessed.
D015415:Biomarkers; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010358:Patient Participation; D017060:Patient Satisfaction; D012107:Research Design; D016896:Treatment Outcome
D015415:Biomarkers